文献速递甲状腺疾病垂体与肾上腺疾病

仑伐替尼治疗甲状腺癌中的皮质醇缺乏:被低估的常见不良事件

Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event.
PubMed 文献 · Thyroid · 2021-12-31

本研究纳入13例接受仑伐替尼治疗的甲状腺癌患者,评估治疗前后垂体/肾上腺轴功能。治疗期间7例(54%)发生肾上腺功能不全(AI),表现为ACTH升高,符合原发性AI(PAI)诊断。PAI可能参与仑伐替尼相关疲劳,糖皮质激素替代可改善疲劳且无需调整仑伐替尼剂量。

要点

  • 仑伐替尼治疗中54%患者发生原发性肾上腺功能不全。
  • 基线ACTH刺激试验皮质醇峰值<646.6 nmol/L提示PAI风险增加。
  • 糖皮质激素替代可改善疲劳,无需减少仑伐替尼剂量。

核心结论

  • 原发性肾上腺功能不全可能是仑伐替尼常见不良事件,并参与相关疲劳。

研究设计与样本

  • 研究纳入13例选择接受仑伐替尼治疗的患者,治疗前后评估肾上腺功能。

主要发现

  • 治疗期间7例(54%)发生原发性肾上腺功能不全,伴ACTH升高。
  • 基线ACTH刺激试验皮质醇峰值<646.6 nmol/L者发生PAI风险增加。
  • 治疗期间11例(84.6%)出现疲劳。
  • PAI组中6/7例(85.7%)经醋酸可的松治疗后疲劳改善,无需调整仑伐替尼剂量。

关键数值与推荐

  • 肾上腺功能评估包括皮质醇、ACTH水平及ACTH(250 μg)刺激试验。
  • 基线ACTH刺激试验皮质醇峰值<646.6 nmol/L提示PAI风险增加。

临床怎么用

  • 仑伐替尼治疗期间应监测垂体/肾上腺轴功能,尤其出现疲劳时。
  • 确诊PAI后可给予糖皮质激素替代以改善疲劳,无需减少仑伐替尼剂量。

局限性

  • 样本量小(13例),结果为初步发现,需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Lenvatinib treatment has shown a significant improvement in progression-free survival in patients with metastatic, progressive, radioiodine-refractory differentiated thyroid cancer, although its use is associated with considerable toxicity. Fatigue is one of the most frequent adverse events (AEs). It has been reported that adrenal insufficiency (AI) may be involved in lenvatinib-related fatigue. In our study, we assessed the pituitary/adrenal axis before and during treatment, and the possible involvement of AI in lenvatinib-related fatigue. This was done to clarify the incidence, development, and time course of AI during lenvatinib treatment. Methods: We studied 13 patients who were selected for lenvatinib therapy. Adrenal function was evaluated by measuring cortisol and adrenocorticotropic hormone (ACTH) levels and through the ACTH (250 μg) stimulation test. Results: During treatment, seven patients (54%) developed AI. High levels of ACTH were observed in accordance with the diagnosis of primary AI (PAI). By evaluating the first ACTH test, before starting lenvatinib treatment, we found that patients with <646.6 nmol/L cortisol peak had an increased risk of developing PAI during lenvatinib treatment. Fatigue was observed in 11 patients (84.6%) during lenvatinib treatment. Cortisone acetate treatment induced an improvement in fatigue in six of seven patients (85.7%) in the PAI group, without the need to change the lenvatinib dosage. Conclusions: PAI may be considered one of the most common AEs associated with lenvatinib. Our data strongly suggest that PAI could be involved in lenvatinib-associated fatigue, particularly in patients with extreme fatigue. In this context, early diagnosis of PAI is essential, especially since glucocorticoid replacement therapy can induce a significant improvement in fatigue, without the need to reduce the dosage of lenvatinib. However, further studies are required to confirm these preliminary findings.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Monti S, Presciuttini F, Deiana MG, et al. Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event. Thyroid. 2021. PMID: 34663079. doi:10.1089/thy.2021.0040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。